Bio-TechneMEX:TECH 83 EBITDA Margin % is 31.40% as of Mar. 2026, which is 0% below its 10-year median of 31.53. GuruFocus rates MEX:TECH with a GF Score™ of 83/100 and a GF Value™ of MXN1,117.60. The stock has 8 warning signs investors should review. Among 944 Biotechnology companies, Bio-Techne ranks better than 83.69% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bio-Techne's EBITDA for the
three
months ended in Mar. 2026 was MXN1,764 Mil. Bio-Techne's Revenue for the
three
months ended in Mar. 2026 was MXN5,616 Mil. Therefore, Bio-Techne's EBITDA margin for the quarter that ended in Mar. 2026 was 31.40%.
Bio-Techne (MEX:TECH) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bio-Techne EBITDA Margin % Related Terms
Bio-Techne EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bio-Techne's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:TECH vs HALO, IBRX, NUVL: EBITDA Margin % Comparison
For the Biotechnology subindustry, Bio-Techne's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bio-Techne's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Techne (MEX:TECH) has a EBITDA Margin % of 31.40% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bio-Techne and its competitors. This is near median its historical median of 31.53. Over the past decade, Bio-Techne's EBITDA Margin % has ranged from 17.78 to 51.23. According to the industry distribution chart, Bio-Techne ranks #154 out of 944 companies in the Biotechnology industry, placing it in the top 16.3%.
Is Bio-Techne's EBITDA Margin % too high?
Bio-Techne's current EBITDA Margin % of 31.40% is near median its 10-year median of 31.53. Over the past 10 years, this metric has ranged from a low of 17.78 to a high of 51.23. Based on the distribution chart, Bio-Techne ranks #154 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bio-Techne has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's EBITDA Margin % compare to HALO and IBRX?
According to the Biotechnology industry distribution chart, Bio-Techne ranks #154 out of 944 companies for EBITDA Margin %. This places Bio-Techne in the top 16% of its industry — outperforming the majority of peers. Historically, Bio-Techne's own EBITDA Margin % has ranged from 17.78 to 51.23 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bio-Techne and its competitors. Bio-Techne's current EBITDA Margin % is 31.40%, which is near median its own 10-year median of 31.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Bio-Techne (MEX:TECH) has a current EBITDA Margin % of 31.40%. The stock's GF Value™ is MXN1,117.60, compared to a current price of MXN1,090.00 — trading 2.5% below its estimated fair value. The current EBITDA Margin % is 31.40%, which is near median its 10-year median of 31.53. Bio-Techne's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bio-Techne (MEX:TECH), the current EBITDA Margin % is 31.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Techne (MEX:TECH) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued.
The current stock price of MXN1,090.00 is trading 2.5% below its estimated GF Value™ of MXN1,117.60.
Key valuation signals for MEX:TECH:
EBITDA Margin %: 31.40% (near median its 10-year median of 31.53)
GF Value™: MXN1,117.60 vs. price of MXN1,090.00 (2.5% below fair value)
No single metric tells the full story. See the MEX:TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
83GF Score
Get the complete analysis for MEX:TECH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TECH has been successfully added to your 
